

Güvenç Koçkaya – Albert Wertheimer

Pharmaceutical Market Access in Emerging Markets



SEEd

Editors

Güvenç Koçkaya

Health Economics and Policy Association, Ankara, Turkey

Albert Wertheimer

College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, FL, USA

© SEEd srl. All rights reserved

Via Vittorio Alfieri, 17 - 10121 Torino, Italia

Tel. +39.011.566.02.58

www.edizioniseed.it – info@edizioniseed.it

First edition

October 2016

ISBN 978-88-97419-63-1

Although the information about medication given in this book has been carefully checked, the author and publisher accept no liability for the accuracy of this information. In every individual case the user must check such information by consulting the relevant literature.

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the Italian Copyright Law in its current version, and permission for use must always be obtained from SEEd Medical Publishers Srl. Violations are liable to prosecution under the Italian Copyright Law.

Summary

Preface	1
1. Introduction to the Market Access	3
Mondher Toumi, Szymon Jarosławski	
1.1 Origin of the Market Access term	3
Market Access for goods	3
Application of the Market Access concept to healthcare: similarities with market economy	3
1.2 Healthcare market specifics	4
1.3 Market Access definition.....	5
1.4 Market Access key concepts	6
What is Access.....	6
What is Value	7
Market Access and the structure of healthcare market.....	8
1.5 Cultural specificities of Market Access	9
1.6 Market Access from payers perspective	10
The payers of healthcare.....	10
Market Access tools to control drug expenditure	11
The Value assessment by payers.....	12
The link between HTA and Pricing & Reimbursement conditions.....	14
Non-HTA tools that affect pricing	14
1.7 Market Access Agreements	15
Definition	15
Taxonomy.....	16
The future	16
1.8 References	17
1.9 To know more	18
2. Market Access in Asian countries	21
Kally Wong	
2.1 Overview on the Healthcare Systems and Healthcare Policies	22
South Korea.....	23
China.....	24
Thailand	26
2.2 Recent Healthcare Policies	28
Thailand	28

South Korea.....	29
China.....	29
2.3 Pathways of Market Access	31
South Korea.....	31
China.....	35
Thailand	41
2.4 Challenges and catalyzers for Market Access.....	47
2.5 Market Outlook	50
2.6 References	52
2.7 To know more	53
3. Market Access in South American Countries	55
Arturo Schweiger, Alejandro Sonis	
3.1 Introduction.....	55
3.2 General economic outlook.....	55
3.3 Health Sector	58
3.4 Pharmaceutical Markets.....	62
3.5 Health Technology Agencies	64
The History of HTA in Latin America.....	65
Red ETSA – Pan-American Health Organization (PAHO/WHO).....	67
How the future looks?	68
3.6 Market access.....	68
Mexico	69
Colombia.....	69
Access to Mexico.....	70
Access to Colombia.....	70
3.7 Final Comments	71
3.8 To know more	72
4. Market Access in South Eastern Europe Countries	77
Tarik Čatić	
4.1 Introduction.....	77
Historical influence and heritage of healthcare sector	78
4.2 General Outlook of Healthcare System and Health Policies	78
Albania.....	78
Bosnia and Herzegovina	81
Kosovo	81
Macedonia, FYR.....	82
Montenegro.....	83
Serbia	83

4.3	Pathways of Market Access (Regulation and Reimbursement).....	84
	Albania.....	84
	Kosovo.....	86
4.4	Mapping and structure of Decision Makers.....	86
	Albania.....	86
	Bosnia and Herzegovina.....	87
	Macedonia, FYR.....	89
	Montenegro.....	90
	Serbia.....	90
4.5	Challenges and catalyzers for Market Access and Look-up for Near Future.....	91
	Albania.....	91
	Bosnia and Herzegovina.....	91
	Kosovo.....	92
	Macedonia, FYR.....	92
	Montenegro.....	92
	Serbia.....	92
4.6	References.....	92
5.	Market Access in North Eastern Europe Countries.....	95
	Esin Tuna	
5.1	General Outlook of Healthcare System and Health Policies.....	95
	Russia.....	95
	Poland.....	97
	Ukraine.....	101
5.2	Pathways of Market Access.....	102
	Russia.....	102
	Poland.....	105
	Ukraine.....	107
5.3	Mapping and Structure of Decision Makers.....	110
	Russia.....	110
	Poland.....	111
	Ukraine.....	113
5.4	Challenges and Catalyzers for Market Access.....	114
	Russia.....	114
	Poland.....	115
	Ukraine.....	117
5.5	Good Examples from Successful Market Access Strategies.....	118
	Russia.....	118
	Poland.....	119
	Ukraine.....	120
5.6	Look up for near future.....	120
	Russia.....	120

Poland	122
Ukraine	123
5.7 References	124

6. Market Access in the United Arab Emirates and Selected Middle Eastern Countries.....129

Ola Ghaleb Al Ahdab	
6.1 The Middle East	129
The Gulf Cooperation Council	129
6.2 Introduction.....	130
6.3 General Outlook of Healthcare System and Health Policies in the UAE and Other ME Countries	130
The United Arab Emirates (UAE)	130
The Executive Board of the Health Ministers for Arab GCC	133
Kingdom of Saudi Arabia (KSA)	134
Jordan.....	135
Egypt.....	135
Lebanon	136
6.4 Pathways of Market Access	136
The United Arab Emirates (UAE)	139
The Executive Board of the Health Ministers for Arab GCC	142
Kingdom of Saudi Arabia (KSA)	144
Jordan.....	145
Egypt.....	146
Lebanon.....	147
6.5 Mapping and Structure of Decision Makers	148
6.6 Challenges and Catalyzers for Market Access	149
The United Arab Emirates (UAE)	149
Challenges: Industry Perspectives	151
6.7 Examples from Market Access Strategies.....	152
Non Communicable Disease (NCD) – Patient Assistance Programs – Oncology, Differential Pricing Strategy.....	152
Non Communicable Disease – Diabetes, Public Private Partnership Aimed at Capacity Building Through an Integrated Educational Platform	153
Access to Innovation – 1 st Oral Multiple Sclerosis Therapy Regulatory Fast Track Introduction	154
Access to Unmet Need – Curative Hepatitis C Virus (HCV) Therapies.....	155
Non Communicable Disease – Diabetes, Payer Partnership – Disease Management Program	155
6.8 Look up for the Near Future	156
6.9 Executive Summary.....	157
6.10 Acknowledgements.....	158
6.11 References	158

7. Market Access in Sub-Saharan Africa countries	163
Debra Leong, Mark Banfield, Anne Smart	
7.1 Regional Considerations for Sub-Saharan African Countries and South Africa as a Case Study.....	163
7.2 Kenya.....	166
7.3 Nigeria.....	167
7.4 South Africa	167
General Outlook of Healthcare System and Health Policies.....	169
Pathways of Market Access (Regulation, Pricing, and Reimbursement).....	172
Mapping and Structure of Decision Makers.....	181
Challenges and Catalyzers for Market Access.....	182
7.5 Good Examples From Successful Market Access Strategies.....	184
7.6 Outlook for the Near Future.....	185
7.7 References.....	186
7.8 To know more	188
8. Market Access in Turkey	193
Fatma Betül Yenilmez	
8.1 General Overview of Healthcare System and Health Policies.....	193
8.2 Pathways of Market Access (Regulation, Pricing, and Reimbursement).....	194
Pharmaceutical Licensing.....	194
Pharmaceuticals Pricing.....	195
Pharmaceutical Reimbursement.....	196
8.3 Mapping and Structure of Decision-Makers.....	196
8.4 Challenges and Catalysts for Market Access.....	197
Challenges.....	197
Catalysts.....	198
8.5 Good Examples from Successful Market Access Strategies.....	198
Good Manufacturing Practice (GMP) Audit.....	198
Promoting Generics.....	199
8.6 Look-up for Near Future.....	199
8.7 References.....	200
9. Comparing the Market Access and HTA process of Selected Countries from Different Regions.....	201
Metin Saylan, Özge Dokuyucu	
9.1 Introduction.....	201
9.2 Comparing HTA systems.....	202
Scope and perspective.....	202

Process and methodology	203
Impact and outcome.....	203
Quality	203
9.3 Conclusions.....	204
9.4 References	205
10. The Future of Market Access.....	207
Albert I. Wertheimer	
10.1 The Market Access Avenues	207
Health Economics.....	208
Knowledgeable Opinion Leaders (KOLs)	208
Value Pricing	209
Value-added Services.....	209
Joint Education/Prevention and Screening.....	210
Personal Relationship Building	211
Softening the Gatekeeper	211
Advisory Boards.....	212
Other Market Access Endeavors	212
Pricing.....	213
10.2 Conclusion	213
10.3 To know more	213
11. Conclusions.....	215
Güvenç Koçkaya	
11.1 References	217
Glossary.....	219
Authors.....	227

Preface

The definition of Market Access was first reported by the World Trade Organization as “to open markets for trade and improve transparency, reciprocity and non-discrimination in international trade”. But Market Access in pharmaceuticals is different than regular products like television, clothing, or cars. For these, the definition of market access for pharmaceuticals could be achieving the optimal price for a product or service and/or maximum reimbursement for the approved target population with no restrictions on funding for the medical technology.

By the way, market access is not only market authorization. It covers market authorization also, but more than market authorization including overlapping activities like pricing, health technology assessment, formulary and reimbursement. Especially pricing and reimbursement are the key factors of market access. Market access is one of most important activities for pharmaceutical companies nowadays.

Lets make examples;

- Think of a company that markets the most innovative products in the market. However, none of the products are secured through market access. Will anyone buy the shares? Possibly not.
- Think a patient where there is a current treatment available. However, her/his country`s MA process for the pharmaceutical is not finished yet. Can she/he reach the treatment? Possibly not and the suffering continues.
- Think a physician who wants to prescribe a pharmaceutical. However, the pharmaceutical is not covered under reimbursement. Can she/he prescribe it easily, especially an innovative high priced drug? Possibly not and again the treatment may not be available.

Depending on all these, market access is the key for pharmaceutical companies. We think these definitions are important and different enough to justify this book about market access. Emerging countries are important for the multinational pharmaceutical companies. It was reported that CAGR was 6.0 percent in the period from 2011-2017, and expected sales exceeding USD 1.1 trillion by 2017. In additional, CAGR 2008-2012 for recent launched pharmaceuticals were 9,8% for Emerging Countries and 1.5% for the top 8 developed countries. Depending on all of this knowledge, emerging countries can`t be ignored by multinational pharmaceutical companies for launching new products. So the market access process in emerging countries will be important in the near future also.

The market access processes in the most important countries in the selected regions are defined in this book and we hope it may help the local experts who are in the beginning or in middle of their careers, the government officers who are lookin for new implementations and examples from other countries, the headquarters managements who want to learn more about emerging markets.

Güvenç Koçkaya, Albert I. Wertheimer

1. Introduction to the Market Access

Mondher Toumi, Szymon Jaroslowski

1.1 Origin of the Market Access term

Market Access for goods

The Market Access (MA) term was first introduced by the World Trade Organization (WTO) to define the competing relationship between the domestic and the imported products of a country [1].

The WTO defines MA as a set of conditions, tariff and non-tariff measures, agreed by WTO members for the entry of specific goods into their markets, that is to say the government policies regarding trade-barriers in general, and specifically the issues of import substitution (to promote local production) and free competition.

There are two types of trade barriers established by countries [1]:

- Tariff measures are taxes on imports of commodities into a country or region. Tariff commitments for goods are set out in each member's schedules of concessions on goods;
- Non-Tariff Barriers/Measures are any measure other than import duties (tariffs) used to restrict imports.

Whereas tariff barriers have steadily declined over the past few years, non-tariff barriers, such as technical regulations, safety or sanitary measures, have been increasing. Other non-tariff barriers are import prohibitions, requirement of a distribution network or effective means of marketing or of homologation for a product in a given country.

Application of the Market Access concept to healthcare: similarities with market economy

The concept of MA can easily be adopted for pharmaceuticals. For example, certification or homologation in the case of machinery is equivalent to the Marketing Authorization that is necessary in the pharmaceutical field in order to access a new market. Remaining trade barriers mentioned above also apply to the pharmaceutical market.

- Tariff Barriers on pharmaceuticals: As most countries import pharmaceutical products, they charge import tariffs, value-added tax (VAT), and other domestic taxes on these products to generate revenue and protect the local manufacturers from competition. E.g. Nigeria, Pakistan, India and China all have significant local pharmaceutical industries and are among countries with the highest import duties. The global trend has however been to reduce or eliminate tariffs and taxes on medicines in order to stimulate trade, competition, and the scaling down of prices [2].

- **Non-Tariff Barriers on pharmaceuticals:** Non-tariff measures have dramatically increased in the pharmaceutical field. The pharmaceutical industry is one of the most regulated. Complex measures range from marketing authorization, efficacy and safety controls, quality standards, pricing and reimbursement of pharmaceutical products, to import and distribution regulations, etc. Most governments have mandatory procedures to ensure the safety and efficacy of the medicines distributed on their market. Requirements for registration may involve specific local clinical studies that are not necessarily justified clinically. An increasing number of countries require clinical trials of a new product to be conducted or repeated on their territory. E.g. in China and Russia early clinical tests, as well as pivotal trials need to be repeated locally, which may take up to five years [3].

Finally, achieving positive reimbursement recommendation in countries with significant health insurance population coverage has become the most complex obstacle pharmaceutical companies need to face.

1.2 Healthcare market specifics

In spite of many similarities between healthcare products and other goods in a free market economy, the former is a unique field that challenges the traditional economic paradigm. There are four features that clearly differentiate the healthcare market from other markets.

- **The price is not determined by supply and demand.** In a traditional market economy context, the price is determined by supply and demand. A single entity assumes the functions of the buyer, the payer, and the consumer. In the healthcare market however, the prices are determined by payers through negotiation or are simply notified by the manufacturer. The buyer is the physician who prescribes the treatment, the payer is the health insurance provider, and the consumer is the patient. The three parties do not necessarily have convergent views on how healthcare should be delivered and what are the priorities.
- **Payers are committed to purchase health for the society.** The payer's intent is to provide health for the patient. When payers fund medicine they fund health production. They can only buy a proxy of health through the purchase of medicine and healthcare services. The actual outcome in terms of health improvement remains uncertain.
- **Health is specific to each individual.** Unlike food, real estate or technology, health cannot be shared or traded between individuals. The outcome of a treatment or a procedure also depends on individual characteristics of the patient [4]. The patients' characteristics may be not fully known *a priori* because of the lack of appropriate tools. This repertoire of scientific tools is evolving fast and changes regularly our understanding and approach to disease and therapies.
- **Externality of health.** Medicines can have a positive impact on the health of people, other than those who consume it. This is particularly the case for vaccinations